RyboDyn expands strategic cancer immunotherapy collaboration with Moffitt Cancer Center

Labcorp and Roche collaborate to expand access to advanced precision testing

Labcorp announced its first U.S. commercial laboratory with an agreement to implement Roche’s cobas Mass Spec solution. This collaboration introduces fully automated mass spectrometry into routine clinical practice—accelerating turnaround times, improving accuracy, and expanding access to advanced diagnostics for patients and providers nationwide.

January 30, 2026

Vol.52 No.04

Drugs & Targets

HanchorBio and WuXi Biologics form partnership to advance next-generation bi-and multi-functional fusion protein pipeline

HanchorBio, a global clinical-stage biotechnology company, and WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization, jointly announced the signing of a strategic collaboration agreement to support the development and manufacturing of multiple next-generation bi- and multi-functional fusion programs from HanchorBio’s pipeline.

January 30, 2026

Vol.52 No.04

Clinical Roundup

Mutation predicts chemoresistance and better responses to immunotherapy in advanced bladder cancer, MD Anderson study finds

Researchers at The University of Texas MD Anderson Cancer Center have determined that mutations in the KDM6A gene—common in advanced bladder cancer—may serve as a predictive biomarker to determine which patients are less likely to benefit from standard chemotherapy but may respond better to immunotherapy.

January 16, 2026

Vol.52 No.02

Drugs & Targets

Verana Health and COTA merge to accelerate research-ready oncology real-world evidence

Verana Health and COTA Inc. are merging with the aim of providing data and software solutions for real-world insights that accelerate clinical research, expedite treatment options, and improve patient care.

January 16, 2026

Vol.52 No.02

Composite intelligence: How AI-driven biomarkers are setting the bar in immuno-oncology

Immune-checkpoint inhibitors (ICIs) transformed treatment paradigms in dozens of malignancies, yet oncologists still confront a deceptively simple question at every consult: Will this individual patient benefit and at what cost?

January 09, 2026

Vol.52 No.1

By Ofer Sharon, Michal Harel and Yehonatan Elon

In Brief

American Center for Cures and BlueCloudX collaborate to accelerate cures, modernize healthcare and clinical research

American Center for Cures and BlueCloudX announced a strategic collaboration aimed at accelerating the development of cures for major diseases while dramatically reducing the time, cost, and complexity of clinical research.

January 09, 2026

Vol.52 No.1

RyboDyn expands strategic cancer immunotherapy collaboration with Moffitt Cancer Center

YOU MAY BE INTERESTED IN

Labcorp and Roche collaborate to expand access to advanced precision testing

HanchorBio and WuXi Biologics form partnership to advance next-generation bi-and multi-functional fusion protein pipeline

Mutation predicts chemoresistance and better responses to immunotherapy in advanced bladder cancer, MD Anderson study finds

Verana Health and COTA merge to accelerate research-ready oncology real-world evidence

Composite intelligence: How AI-driven biomarkers are setting the bar in immuno-oncology

American Center for Cures and BlueCloudX collaborate to accelerate cures, modernize healthcare and clinical research

Renew today!

Subscriber content

Never miss an issue!

Login